S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Sverre E. Kjeldsen,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Thomas G. von Lueder,Otto A. Smiseth,Otto A. Smiseth,Kristian Wachtell,Nisha Mistry,Arne Westheim,Ingrid Hopper,Stevo Julius,Bertram Pitt,Christopher M. Reid,Christopher M. Reid,Richard B. Devereux,Faiez Zannad +15 more
TL;DR: It is argued that RAAS blockers including MRAs (mineralocorticoid receptor antagonists; aldosterone antagonists) should be used in the treatment of patients with HFpEF, based on considerations of well-established clinical efficacy in hypertension and heart failure with reduced ejection fraction.
Journal ArticleDOI
Racial Differences in Incident Heart Failure During Antihypertensive Therapy
TL;DR: The increased risk of developing new HF in blacks persists after adjusting for the higher prevalence of HF risk factors in blacks, for treatment effects and in-treatment blood pressure, and for the known predictive value of the ECG strain pattern and in -treatment ECG LVH and QRS duration for incident HF in this population.
Journal ArticleDOI
Whole Blood Viscosity, Blood Pressure and Cardiovascular Risk Factors in Healthy Blood Donors
TL;DR: Results suggest that even in a population of healthy normotensive blood donors of a wide age range and either gender, there are positive correlations between directly assessed whole blood viscosity and a number of the components of the metabolic cardiovascular syndrome including systolic blood pressure, weight and blood lipids.
Journal ArticleDOI
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
TL;DR: The need for randomized evaluation of treatment to more aggressive vs. conventional SBP targets is supported, aschieved SBP 130 mmHg or less is not associated with lower cardiovascular risk and is associated with a significantly increased risk of death and trend towards increased cardiovascular mortality.
Journal ArticleDOI
Increased platelet size and release reaction in essential hypertension.
TL;DR: Findings point to increased platelet activity in essential hypertension, particularly in arterial blood, in men with untreated mild essential hypertension and compared with age-matched normotensive men.